NeoGenomics Inc (NEO)

[rusty8350]

Fourth Quarter 2013 Highlights:

Revenue growth of 23%
Test volume growth of 28%
Gross Profit Margin of 50.0% versus 43.2% last year
Adjusted EBITDA(1) growth of 90%
Net Income of $0.02 per share versus $0.00 last year

So, if they're profitable right now by a margin of .02 per share but expect reductions in reimbursement that will total .04 per share losses in 2014 due to the new FISH regulations, this means it could potentially send Neogenomics back into the unprofitable zone....

I see why it's better to read news and not just the headline....